Kenacort-A 10

Triamcinolone Acetonide, the active ingredient in Kenacort-A 10, is a corticosteroid (glucocorticoid) presented as a 10 mg/mL injectable solution for intraarticular, intradermal, and intramuscular use. It reduces inflammation and modulates immune responses in conditions such as arthritis, bursitis, tendinitis, dermatitis, and allergic reactions.

GNH USA supplies Kenacort-A 10 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kenacort‑A 10 (triamcinolone acetonide) is a glucocorticoid used to manage inflammatory and immune‑mediated conditions.

- Arthritis: reduces joint inflammation and pain, improving mobility. - Bursitis: diminishes bursal swelling and discomfort. - Tendinitis: alleviates tendon inflammation and restores function. - Dermatitis: lessens skin inflammation, redness, and itching. - Allergic reactions: suppresses hypersensitivity responses and relieves symptoms.

Kenacort‑A 10 may cause a range of adverse reactions, most of which are related to its corticosteroid activity.

Common Side Effects: - Injection‑site pain or irritation. - Transient flushing or warmth. - Elevated blood glucose levels. - Mild headache or dizziness. - Localized bruising.

Serious or Rare Side Effects: - Adrenal axis suppression leading to cortisol deficiency. - Severe allergic reaction (anaphylaxis). - Opportunistic infections or reactivation of latent infections. - Osteonecrosis of the jaw or long bones. - Hypercortisolism with systemic effects such as hypertension and mood changes.

Before using Kenacort‑A 10, consider the following safety measures.

- Pregnancy: Category C; use only when potential benefit justifies potential risk to the fetus. - Breastfeeding: Caution; corticosteroid may be excreted in milk and affect the infant. - Systemic infection: Avoid use in patients with active untreated bacterial, viral, or fungal infections. - Diabetes: Monitor blood glucose closely as glucocorticoids can raise glucose levels. - Osteoporosis: Long‑term or high‑dose therapy may exacerbate bone loss; assess risk. - Store at room temperature: keep in the original container, protect from light and moisture.

Kenacort‑A 10 can interact with several drug classes; awareness helps minimize adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may increase systemic corticosteroid exposure. - Live vaccines (e.g., measles, varicella) can lead to uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) increase risk of gastrointestinal ulceration or bleeding. - Diuretics may potentiate hypokalemia; monitor electrolytes. - Antidiabetic agents may require dose adjustment because of hyperglycaemic effect. - ACE inhibitors or ARBs can enhance potassium retention; watch serum potassium levels.